Bridging Intestinal Failure With Teduglutide - a Case Report

In this case report the investigators present a novel strategy for using teduglutide as a bridging therapy to intestinal reconstruction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Short Bowel Syndrome Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Malabsorption Syndromes Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications

Sex eligibility

Male

Study type

Observational

Primary location

Medical University of Vienna

Vienna, Austria

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

short bowel syndrome

Exclusion criteria

<18 years

Treatment and study plan

Teduglutide

Drug

bridging intestinal failure with teduglutide until reconstruction

Primary outcomes

enteral autonomy (complete discontinuation of parenteral support)

Time frame: 6 months

observe if enteral autonomy may be achieved before reconstruction

Sponsors and collaborators

Lead sponsor

Medical University of Vienna

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Jun 7, 2021
Registry last updated: Jun 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed